Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sevoflurane + sufentanil is a combination anesthetic regimen commonly employed for the induction and maintenance of balanced general anesthesia. Sevoflurane is a volatile, halogenated ether inhalation anesthetic that primarily acts by modulating GABA-A and glycine receptors, leading to unconsciousness, amnesia, and muscle relaxation. Sufentanil is a highly potent synthetic opioid analgesic that acts as a selective agonist at the mu-opioid receptor, providing intense perioperative analgesia and blunting the sympathetic response to surgical stimuli. This combination is frequently used in major surgical procedures, such as oncology surgeries and lymph-node dissections, to provide stable hemodynamic control and facilitate rapid emergence from anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sevoflurane + sufentanil.